{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T12:37:12Z","timestamp":1792931832023,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA033572"],"award-info":[{"award-number":["P30CA033572"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA290007"],"award-info":[{"award-number":["R01CA290007"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031022","name":"Center for Cancer Research","doi-asserted-by":"publisher","award":["U01CA250046"],"award-info":[{"award-number":["U01CA250046"]}],"id":[{"id":"10.13039\/100031022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Syst Biol Appl"],"DOI":"10.1038\/s41540-026-00675-6","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T11:48:01Z","timestamp":1773920881000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Overcoming vascular niche\u2013mediated TKI resistance in acute myeloid leukemia through miR-126 inhibition"],"prefix":"10.1038","volume":"12","author":[{"given":"Matthew","family":"Froid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Branciamore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Frankhouser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hsuan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer Rangel","family":"Ambriz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le Xuan Troung","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihyun","family":"Irizarry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Huei","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"O\u2019Meally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Marcucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Rockne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Basanta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"675_CR1","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.blre.2017.03.004","volume":"31","author":"MS Shafat","year":"2017","unstructured":"Shafat, M. S. et al. The bone marrow microenvironment\u2013Home of the leukemic blasts. Blood Rev. 31, 277\u2013286 (2017).","journal-title":"Blood Rev."},{"key":"675_CR2","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/nm0797-730","volume":"3","author":"D Bonnet","year":"1997","unstructured":"Bonnet, D. & Dick, J. E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3, 730\u2013737 (1997).","journal-title":"Nat. Med."},{"key":"675_CR3","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/s41420-022-01193-0","volume":"8","author":"Y Chen","year":"2022","unstructured":"Chen, Y. et al. The genesis and evolution of acute myeloid leukemia stem cells in the microenvironment: from biology to therapeutic targeting. Cell Death Discov. 8, 397 (2022).","journal-title":"Cell Death Discov."},{"key":"675_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1196\/annals.1349.001","volume":"1044","author":"JE Dick","year":"2005","unstructured":"Dick, J. E. Acute myeloid leukemia stem cells. Ann. N. Y. Acad. Sci. 1044, 1\u20135 (2005).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"675_CR5","doi-asserted-by":"publisher","first-page":"873. e1","DOI":"10.1016\/j.jtct.2021.05.016","volume":"27","author":"JP Bewersdorf","year":"2021","unstructured":"Bewersdorf, J. P. et al. Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis\u2014a systematic review and meta-analysis. Transplant. Cell. Ther. 27, 873. e1\u2013873 (2021).","journal-title":"Transplant. Cell. Ther."},{"key":"675_CR6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.hemonc.2017.05.021","volume":"10","author":"AA Kassim","year":"2017","unstructured":"Kassim, A. A. & Savani, B. N. Hematopoietic stem cell transplantation for acute myeloid leukemia: a review. Hematol.\/Oncol. Stem Cell Ther. 10, 245\u2013251 (2017).","journal-title":"Hematol.\/Oncol. Stem Cell Ther."},{"key":"675_CR7","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.bbmt.2015.10.019","volume":"22","author":"A Rashidi","year":"2016","unstructured":"Rashidi, A. et al. Outcomes of allogeneic stem cell transplantation in elderly patients with acute myeloid leukemia: a systematic review and meta-analysis. Biol. Blood Marrow Transplant. 22, 651\u2013657 (2016).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"675_CR8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/hon.3076","volume":"41","author":"FA Lagunas-Rangel","year":"2023","unstructured":"Lagunas-Rangel, F. A. DNA damage accumulation and repair defects in FLT3-ITD acute myeloid leukemia: implications for clonal evolution and disease progression. Hematol. Oncol. 41, 26\u201338 (2023).","journal-title":"Hematol. Oncol."},{"key":"675_CR9","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/sj.leu.2403838","volume":"19","author":"M Yanada","year":"2005","unstructured":"Yanada, M. et al. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. Leukemia 19, 1345\u20131349 (2005).","journal-title":"Leukemia"},{"key":"675_CR10","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1038\/s41375-022-01687-x","volume":"36","author":"C Allert","year":"2022","unstructured":"Allert, C. et al. Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML. Leukemia 36, 2418\u20132429 (2022).","journal-title":"Leukemia"},{"key":"675_CR11","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.3390\/cancers14143398","volume":"14","author":"TE Knight","year":"2022","unstructured":"Knight, T. E. et al. FLipping\u201d the story: FLT3-mutated acute myeloid leukemia and the evolving role of FLT3 inhibitors. Cancers 14, 3398 (2022).","journal-title":"Cancers"},{"key":"675_CR12","doi-asserted-by":"publisher","first-page":"5873","DOI":"10.3390\/ijms22115873","volume":"22","author":"M Loschi","year":"2021","unstructured":"Loschi, M. et al. FLT3 tyrosine kinase inhibitors for the treatment of fit and unfit patients with FLT3-mutated AML: a systematic review. Int. J. Mol. Sci. 22, 5873 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"675_CR13","doi-asserted-by":"publisher","first-page":"6429","DOI":"10.3390\/jcm12206429","volume":"12","author":"C Negotei","year":"2023","unstructured":"Negotei, C. et al. A review of FLT3 kinase inhibitors in AML. J. Clin. Med. 12, 6429 (2023).","journal-title":"J. Clin. Med."},{"key":"675_CR14","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/nm.4499","volume":"24","author":"B Zhang","year":"2018","unstructured":"Zhang, B. et al. Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia. Nat. Med. 24, 450\u2013462 (2018).","journal-title":"Nat. Med."},{"key":"675_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-021-01133-y","volume":"14","author":"B Zhang","year":"2021","unstructured":"Zhang, B. et al. Treatment-induced arteriolar revascularization and miR-126 enhancement in bone marrow niche protect leukemic stem cells in AML. J. Hematol. Oncol. 14, 1\u201319 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"675_CR16","doi-asserted-by":"publisher","first-page":"6154","DOI":"10.1038\/s41467-021-26420-7","volume":"12","author":"L Zhang","year":"2021","unstructured":"Zhang, L. et al. Targeting miR-126 in inv (16) acute myeloid leukemia inhibits leukemia development and leukemia stem cell maintenance. Nat. Commun. 12, 6154 (2021).","journal-title":"Nat. Commun."},{"key":"675_CR17","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ccell.2015.12.011","volume":"29","author":"ER Lechman","year":"2016","unstructured":"Lechman, E. R. et al. miR-126 regulates distinct self-renewal outcomes in normal and malignant hematopoietic stem cells. Cancer Cell 29, 214\u2013228 (2016).","journal-title":"Cancer Cell"},{"key":"675_CR18","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1161\/01.CIR.0000132468.82942.F5","volume":"109","author":"SE Epstein","year":"2004","unstructured":"Epstein, S. E. et al. Janus phenomenon: the interrelated tradeoffs inherent in therapies designed to enhance collateral formation and those designed to inhibit atherogenesis. Circulation 109, 2826\u20132831 (2004).","journal-title":"Circulation"},{"key":"675_CR19","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1038\/s41375-023-01933-w","volume":"37","author":"J Qiao","year":"2023","unstructured":"Qiao, J. et al. Targeting miR-126 in ph+ acute lymphoblastic leukemia. Leukemia 37, 1540\u20131544 (2023).","journal-title":"Leukemia"},{"key":"675_CR20","doi-asserted-by":"publisher","first-page":"e610","DOI":"10.1002\/ctm2.610","volume":"11","author":"H Wang","year":"2021","unstructured":"Wang, H. et al. Targeting miR-126 disrupts maintenance of myelodysplastic syndrome stem and progenitor cells. Clin. Transl. Med. 11, e610 (2021).","journal-title":"Clin. Transl. Med."},{"key":"675_CR21","doi-asserted-by":"publisher","first-page":"677","DOI":"10.3390\/cancers13040677","volume":"13","author":"A Araujo","year":"2021","unstructured":"Araujo, A. et al. Quantification and optimization of standard-of-care therapy to delay the emergence of resistant bone metastatic prostate cancer. Cancers 13, 677 (2021).","journal-title":"Cancers"},{"key":"675_CR22","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1038\/s41467-024-46594-0","volume":"15","author":"RT Bishop","year":"2024","unstructured":"Bishop, R. T. et al. The bone ecosystem facilitates multiple myeloma relapse and the evolution of heterogeneous drug resistant disease. Nat. Commun. 15, 2458 (2024).","journal-title":"Nat. Commun."},{"key":"675_CR23","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s10585-014-9674-1","volume":"31","author":"J Gallaher","year":"2014","unstructured":"Gallaher, J. et al. Improving treatment strategies for patients with metastatic castrate resistant prostate cancer through personalized computational modeling. Clin. Exp. Metastasis 31, 991\u2013999 (2014).","journal-title":"Clin. Exp. Metastasis"},{"key":"675_CR24","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jtbi.2012.02.002","volume":"301","author":"P Macklin","year":"2012","unstructured":"Macklin, P. et al. Patient-calibrated agent-based modelling of ductal carcinoma in situ (DCIS): from microscopic measurements to macroscopic predictions of clinical progression. J. Theor. Biol. 301, 122\u2013140 (2012).","journal-title":"J. Theor. Biol."},{"key":"675_CR25","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.tcb.2022.10.006","volume":"33","author":"J West","year":"2023","unstructured":"West, J., Robertson-Tessi, M. & Anderson, A. R. Agent-based methods facilitate integrative science in cancer. Trends Cell Biol. 33, 300\u2013311 (2023).","journal-title":"Trends Cell Biol."},{"key":"675_CR26","first-page":"2984","volume":"114","author":"PP Zarrinkar","year":"2009","unstructured":"Zarrinkar, P. P. et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood, J. Am. Soc. Hematol. 114, 2984\u20132992 (2009).","journal-title":"Blood, J. Am. Soc. Hematol."},{"key":"675_CR27","doi-asserted-by":"publisher","first-page":"6857","DOI":"10.3390\/ijms22136857","volume":"22","author":"S Bruno","year":"2021","unstructured":"Bruno, S. et al. The role of hypoxic bone marrow microenvironment in acute myeloid leukemia and future therapeutic opportunities. Int. J. Mol. Sci. 22, 6857 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"675_CR28","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ccell.2017.08.001","volume":"32","author":"D Passaro","year":"2017","unstructured":"Passaro, D. et al. Increased vascular permeability in the bone marrow microenvironment contributes to disease progression and drug response in acute myeloid leukemia. Cancer Cell 32, 324\u2013341 (2017).","journal-title":"Cancer Cell"},{"key":"675_CR29","doi-asserted-by":"publisher","first-page":"4326","DOI":"10.1182\/bloodadvances.2019000937","volume":"3","author":"D Pollyea","year":"2019","unstructured":"Pollyea, D. et al. Erratum: venetoclax for AML: changing the treatment paradigm. Blood Adv. 3, 4326\u20134335 (2019).","journal-title":"Blood Adv."},{"key":"675_CR30","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1093\/imammb\/dqi005","volume":"22","author":"AR Anderson","year":"2005","unstructured":"Anderson, A. R. A hybrid mathematical model of solid tumour invasion: the importance of cell adhesion. Math. Med. Biol. J. IMA 22, 163\u2013186 (2005).","journal-title":"Math. Med. Biol. J. IMA"},{"key":"675_CR31","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.cell.2006.09.042","volume":"127","author":"AR Anderson","year":"2006","unstructured":"Anderson, A. R. et al. Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell 127, 905\u2013915 (2006).","journal-title":"Cell"},{"key":"675_CR32","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1158\/0008-5472.CAN-13-2652","volume":"74","author":"A Araujo","year":"2014","unstructured":"Araujo, A. et al. An integrated computational model of the bone microenvironment in bone-metastatic prostate cancer. Cancer Res. 74, 2391\u20132401 (2014).","journal-title":"Cancer Res."},{"key":"675_CR33","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1007\/s11538-018-0416-4","volume":"80","author":"A Araujo","year":"2018","unstructured":"Araujo, A. et al. Size matters: metastatic cluster size and stromal recruitment in the establishment of successful prostate cancer to bone metastases. Bull. Math. Biol. 80, 1046\u20131058 (2018).","journal-title":"Bull. Math. Biol."},{"key":"675_CR34","doi-asserted-by":"publisher","first-page":"e13687","DOI":"10.1111\/eva.13687","volume":"17","author":"B Colyer","year":"2024","unstructured":"Colyer, B. et al. A seven-step guide to spatial, agent-based modelling of tumour evolution. Evolut. Appl. 17, e13687 (2024).","journal-title":"Evolut. Appl."},{"key":"675_CR35","doi-asserted-by":"publisher","first-page":"29384","DOI":"10.1038\/srep29384","volume":"6","author":"LM Cook","year":"2016","unstructured":"Cook, L. M. et al. Predictive computational modeling to define effective treatment strategies for bone metastatic prostate cancer. Sci. Rep. 6, 29384 (2016).","journal-title":"Sci. Rep."},{"key":"675_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/CCI.18.00069","volume":"2","author":"J Metzcar","year":"2019","unstructured":"Metzcar, J. et al. A review of cell-based computational modeling in cancer biology. JCO Clin. Cancer Inform. 2, 1\u201313 (2019).","journal-title":"JCO Clin. Cancer Inform."},{"key":"675_CR37","doi-asserted-by":"publisher","first-page":"102884","DOI":"10.1016\/j.artmed.2024.102884","volume":"152","author":"S Stephan","year":"2024","unstructured":"Stephan, S. et al. Agent-based approaches for biological modeling in oncology: A literature review. Artif. Intell. Med. 152, 102884 (2024).","journal-title":"Artif. Intell. Med."},{"key":"675_CR38","doi-asserted-by":"publisher","first-page":"e1007635","DOI":"10.1371\/journal.pcbi.1007635","volume":"16","author":"RR Bravo","year":"2020","unstructured":"Bravo, R. R. et al. Hybrid automata library: a flexible platform for hybrid modeling with real-time visualization. PLoS Comput. Biol. 16, e1007635 (2020).","journal-title":"PLoS Comput. Biol."},{"key":"675_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-017-02376-5","volume":"9","author":"O Akinduro","year":"2018","unstructured":"Akinduro, O. et al. Proliferation dynamics of acute myeloid leukaemia and haematopoietic progenitors competing for bone marrow space. Nat. Commun. 9, 1\u201312 (2018).","journal-title":"Nat. Commun."},{"key":"675_CR40","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13619-024-00188-9","volume":"13","author":"S Chao","year":"2024","unstructured":"Chao, S., Yan, H. & Bu, P. Asymmetric division of stem cells and its cancer relevance. Cell Regener. 13, 5 (2024).","journal-title":"Cell Regener."},{"key":"675_CR41","doi-asserted-by":"publisher","first-page":"316","DOI":"10.4252\/wjsc.v8.i10.316","volume":"8","author":"M Stahl","year":"2016","unstructured":"Stahl, M., Kim, T. K. & Zeidan, A. M. Update on acute myeloid leukemia stem cells: new discoveries and therapeutic opportunities. World J. Stem Cells 8, 316 (2016).","journal-title":"World J. Stem Cells"},{"key":"675_CR42","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.3390\/ijms26094005","volume":"26","author":"S Cao","year":"2025","unstructured":"Cao, S., Wang, Q. & Zhu, G. From chemotherapy to targeted therapy: unraveling resistance in acute myeloid leukemia through genetic and non-genetic insights. Int. J. Mol. Sci. 26, 4005 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"675_CR43","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.3390\/cancers16101819","volume":"16","author":"D Capelli","year":"2024","unstructured":"Capelli, D. FLT3-mutated leukemic stem cells: mechanisms of resistance and new therapeutic targets. Cancers 16, 1819 (2024).","journal-title":"Cancers"},{"key":"675_CR44","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.3390\/biomedicines11123248","volume":"11","author":"LA Murphy","year":"2023","unstructured":"Murphy, L. A. & Winters, A. C. Emerging and future targeted therapies for pediatric acute myeloid leukemia: targeting the leukemia stem cells. Biomedicines 11, 3248 (2023).","journal-title":"Biomedicines"}],"container-title":["npj Systems Biology and Applications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41540-026-00675-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41540-026-00675-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41540-026-00675-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T06:02:36Z","timestamp":1773986556000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41540-026-00675-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["675"],"URL":"https:\/\/doi.org\/10.1038\/s41540-026-00675-6","relation":{},"ISSN":["2056-7189"],"issn-type":[{"value":"2056-7189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"assertion":[{"value":"10 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}